Skip to main content

Market Overview

Merck's Cough Drug Gefapixant Application Accepted For US Review


The FDA has accepted Merck & Co Inc's (NYSE: MRK) marketing application seeking approval for gefapixant, for review.

  • The selective P2X3 receptor antagonist is being developed to treat refractory chronic cough or unexplained chronic cough in adults.
  • The application will be discussed at an upcoming advisory committee meeting.
  • The agency's target action date is set of December 21.
  • The NDA is based on mixed results from the COUGH-1 and COUGH-2 trials.
  • In COUGH-1, the 45-mg dose of gefapixant resulted in an 18.5% estimated relative risk reduction in 24-hour coughs per hour at week 12, its primary endpoint. In COUGH-2, the same dose drove a 14.6% relative risk reduction at week 24. The 15-mg dose failed in both trials.
  • Price Action: MRK shares were up 0.94% at $73.30 in premarket trading on the last check Monday.

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: chronic coughBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at